Adjuvant Therapy in Stage I Carcinoma of the Breast: The Influence of Multigene Analyses and Molecular Phenotyping

• Published in: The breast journal Vol. 18; no. 4; pp. 303 - 311
• Main Authors: Schwartz, Gordon F., Bartelink, Harry, Burstein, Harold J., Cady, Blake, Cataliotti, Luigi, Fentiman, Ian S., Holland, Roland, Hughes, Kevin S., Masood, Shahla, McCormick, Beryl, Palazzo, Juan A., Pressman, Peter I., Reis-Filho, Jorge, Pusztai, Lajos, Rutgers, Emiel J. T., Seidman, Andrew D., Solin, Lawrence J., Sparano, Joseph A.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.07.2012
• Subjects: adjuvant therapy; breast carcinoma; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Chemotherapy, Adjuvant; estrogen receptors; Female; gene analysis; Gene Expression Regulation, Neoplastic; Genetic Testing; Her-2-neu; Humans; Ki-67; Neoplasm Micrometastasis; Neoplasm Staging; progesterone receptors; Prognosis; Receptor, ErbB-2 - metabolism; Receptors, Estrogen - metabolism; Receptors, Progesterone - metabolism; Sentinel Lymph Node Biopsy; Transcriptome
• ISSN: 1075-122X; 1524-4741
• DOI: 10.1111/j.1524-4741.2012.01264.x

:  A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, Nottingham index, patient age and co‐morbidities, but also incorporating steroid hormone and Her‐2‐neu data as well as other immunohistochemical markers. The role of the genetic analysis of breast cancer and proprietary gene prognostic signatures was discussed, along with the molecular profiling of breast cancers into several groups that may predict prognosis. These molecular data are not currently sufficiently mature to make them part of decision making algorithms of recommendations for the treatment of individual patients.